Rodrigo Santos Vicente

Dr. Rodrigo Santos Vicente

Hospital Prof. Dr. Fernando Fonseca, Amadora, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MVMarina Vitorino
Marina Vitorino
Diogo Alpuim CostaDiogo Alpuim Costa
Diogo Alpuim Costa
RVRodrigo Santos Vicente
Rodrigo Santos Vicente
TCTelma Caleça
Telma Caleça
CSCatarina Santos
Catarina Santos
The tumour microenvironment (TME) comprises a complex ecosystem of different cell types, including immune cells, cells of the vasculature and lymphatic system, cancer-associated fibroblasts, pericytes, and adipocytes. Cancer proliferation, invasion, metastasis, drug resistance and immune escape are all influenced by the dynamic interaction between cancer cells and TME. Microbes, such as bacteria, fungi, viruses, archaea and protists, found within tumour tissues, constitute the intratumour microbiota, which is tumour type-specific and distinct among patients with different clinical outcomes. Growing evidence reveals a significant relevance of local microbiota in the colon, liver, breast, lung, oral cavity and pancreas carcinogenesis. Moreover, there is a growing interest in the tumour immune microenvironment (TIME) pointed out in several cross-sectional studies on the correlation between microbiota and TME. It is now known that microorganisms have the capacity to change the density and function of anticancer and suppressive immune cells, enabling the promotion of an inflammatory environment. As immunotherapy (such as immune checkpoint inhibitors) is becoming a promising therapy using TIME as a therapeutic target, the analysis and comprehension of local microbiota and its modulating strategies can help improve cancer treatments.

15 July 2022 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
TTTiago Cruz Tomás
Tiago Cruz Tomás
IEInês Eiriz
Inês Eiriz
MVMarina Vitorino
Marina Vitorino
RVRodrigo Santos Vicente
Rodrigo Santos Vicente
JGJoão Gramaça
João Gramaça
TFTeresa Fiúza
Teresa Fiúza
Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer

Verified
Journal Article
Open access
PDF file
Ana Duarte MendesAna Duarte Mendes
Ana Duarte Mendes
AFAna Rita Freitas
Ana Rita Freitas
RVRodrigo Santos Vicente
Rodrigo Santos Vicente
MVMarina Vitorino
Marina Vitorino
MBMarta Vaz Batista
Marta Vaz Batista
SBSofia Braga
Sofia Braga
Ovarian cancer is one of the most common gynecological malignancies and has low survival rates. One of the main determinants of this unfavorable prognosis is the high rate of peritoneal metastasis at diagnosis, closely related to its morbidity and mortality. The mechanism underlying peritoneal carcinomatosis is not clearly defined, but a clear preference for omental spread has been described. Growing evidence suggests that adipose tissue plays a role in promoting cancer onset and progression. Moreover, obesity can lead to changes in the original functions of adipocytes, resulting in metabolic and inflammatory changes in the adipose tissue microenvironment, potentially increasing the risk of tumor growth. However, the specific roles of adipocytes in ovarian cancer have not yet been fully elucidated. Due to the undeniable link between obesity and cancer, the adipose tissue microenvironment could also present a promising therapeutic target that warrants further research. This review discusses the complex relationship between ovarian cancer and the adipose tissue microenvironment.

18 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TCTelma Caleça
Telma Caleça
PRPedro Casal Ribeiro
Pedro Casal Ribeiro
MVMarina Vitorino
Marina Vitorino
MMMaria Menezes
Maria Menezes
MSMafalda Sampaio-Alves
Mafalda Sampaio-Alves
Diogo Alpuim CostaDiogo Alpuim Costa
Diogo Alpuim Costa
In this first analysis, samples from 23 BC survivors (group 1) and 291 healthy female controls (group 2) were characterised through the V3 and V4 regions that encode the “16S rRNA” gene of each bacteria. The samples were sequenced by next-generation sequencing (NGS), and the taxonomy was identified by resorting to Kraken2 and improved with Bracken, using a curated database called ‘GutHealth_DB’. The α and β-diversity analyses were used to determine the richness and evenness of the gut microbiota. A non-parametric Mann-Whitney U test was applied to assess differential abundance between both groups. The Firmicutes/Bacteroidetes (F/B) ratio was calculated using a Kruskal-Wallis chi-squared test. The α-diversity was significantly higher in group 1 (p = 0.28 × 10−12 for the Chao index and p = 1.64 × 10−12 for the ACE index). The Shannon index, a marker of richness and evenness, was not statistically different between the two groups (p = 0.72). The microbiota composition was different between the two groups: a null hypothesis was rejected for PERMANOVA (p = 9.99 × 10−5) and Anosim (p = 0.04) and was not rejected for β-dispersion (p = 0.158), using Unifrac weighted distance. The relative abundance of 14 phyla, 29 classes, 25 orders, 64 families, 116 genera, and 74 species differed significantly between both groups. The F/B ratio was significantly lower in group 1 than in group 2, p < 0.001. Our study allowed us to observe significant taxonomic disparities in the two groups by testing the differences between BC survivors and healthy controls. Additional studies are needed to clarify the involved mechanisms and explore the relationship between microbiota and BC survivorship.

25 September 2023 in Psycho-Oncology
Verified
Journal Article
Open access
RVRodrigo Santos Vicente
Rodrigo Santos Vicente
AFAna Rita Freitas
Ana Rita Freitas
RFRicardo Miguel Azevedo Ferreira
Ricardo Miguel Azevedo Ferreira
SPSofia Parada Prada
Sofia Parada Prada
TMTelma Sofia Martins
Telma Sofia Martins
MBMiguel Barbosa
Miguel Barbosa
Background: The first medical oncology appointment serves as a platform for patients to comprehend their diagnosis and prognostic implications of cancer. This study aimed to determine patients' communication preferences during their first medical oncology appointment and to assess the disparities between patients' preferences and perceptions.Methods: A total of 169 cancer patients participated by completing the Communication in First Medical Oncology Appointment Questionnaire (C‐FAQ), a two‐section questionnaire designed to assess patients’ preferences and perceptions regarding Content (information provided and its extent), Facilitation (timing and location of information delivery), and Support (emotional support) during their first medical oncology appointment. A comparative analysis was conducted to assess the variations between preferences and perceptions.Results: Content emerged as the most significant dimension compared to Facilitation and Support. The physician's knowledge, honesty, and ability to provide clear information were considered the most important attributes. Patients evaluated most of their preferences as “very important”. Patients’ perception of the communication dimensions present during their appointment was below preferences for 11 items, indicating significant discrepancies in clinical practice.Conclusions: Patients highly valued their preferences concerning Content, Facilitation, and Support dimensions of communication. However, patient preferences were more prominently oriented towards the Content dimension. The discrepancies between preferences and perceptions should be viewed as an opportunity for enhancing communication skills through training.

28 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RVRodrigo Santos Vicente
Rodrigo Santos Vicente
Diogo Alpuim CostaDiogo Alpuim Costa
Diogo Alpuim Costa
MVMarina Vitorino
Marina Vitorino
Ana Duarte MendesAna Duarte Mendes
Ana Duarte Mendes
CSCatarina Santos
Catarina Santos
MFMário Fontes-Sousa
Mário Fontes-Sousa
Germline pathogenic variants in the Breast Cancer Genes 1 (BRCA1) and 2 (BRCA2) are responsible for Hereditary Breast and Ovarian Cancer (HBOC) syndrome. Genetic susceptibility to breast cancer accounts for 5–10% of all cases, phenotypically presenting with characteristics such as an autosomal dominant inheritance pattern, earlier age of onset, bilateral tumours, male breast cancer, and ovarian tumours, among others. BRCA2 pathogenic variant is usually associated with other cancers such as melanoma, prostate, and pancreatic cancers. Many rearrangements of different mutations were found in both genes, with some ethnic groups having higher frequencies of specific mutations due to founder effects. Despite the heterogeneity of germline BRCA1/BRCA2 mutations in Portuguese breast or/and ovarian cancer families, the first described founder mutation in the BRCA2 gene (c.156_157insAlu) and two other variants in the BRCA1 gene (c.3331_3334del and c.2037delinsCC) contribute to about 50% of all pathogenic mutations. Furthermore, the families with the BRCA1 c.3331_3334del or the c.2037delinsCC mutations share a common haplotype, suggesting that these may also be founder mutations in the Portuguese population. Identifying specific and recurrent/founder mutations plays an important role in increasing the efficiency of genetic testing since it allows the use of more specific, cheaper and faster strategies to screen HBOC families. Therefore, this review aims to describe the mutational rearrangements of founder mutations and evaluate their impact on the genetic testing criteria for HBOC families of Portuguese ancestry.